ALTE Stock Overview
A medical device company, provides technology for blood purification during extracorporeal treatment.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Alteco Medical AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.16 |
| 52 Week High | SEK 0.55 |
| 52 Week Low | SEK 0.089 |
| Beta | 0.19 |
| 11 Month Change | -5.29% |
| 3 Month Change | -0.62% |
| 1 Year Change | -36.11% |
| 33 Year Change | -79.88% |
| 5 Year Change | -74.53% |
| Change since IPO | -97.32% |
Recent News & Updates
Shareholder Returns
| ALTE | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -23.3% | -4.8% | -1.4% |
| 1Y | -36.1% | 5.6% | 20.7% |
Return vs Industry: ALTE underperformed the Swedish Medical Equipment industry which returned 10.2% over the past year.
Return vs Market: ALTE underperformed the Swedish Market which returned 25.9% over the past year.
Price Volatility
| ALTE volatility | |
|---|---|
| ALTE Average Weekly Movement | 48.3% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 10.9% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: ALTE's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: ALTE's weekly volatility has increased from 37% to 48% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 4 | n/a | www.altecomedical.com |
Alteco Medical AB, a medical device company, provides technology for blood purification during extracorporeal treatment. Its product portfolio includes Alteco LPS Adsorber, which removes endotoxin from the bloodstream. Alteco Medical AB was founded in 2002 and is based in Lund, Sweden.
Alteco Medical AB Fundamentals Summary
| ALTE fundamental statistics | |
|---|---|
| Market cap | SEK 17.26m |
| Earnings (TTM) | -SEK 7.14m |
| Revenue (TTM) | SEK 3.41m |
5.1x
P/S Ratio-2.4x
P/E RatioIs ALTE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALTE income statement (TTM) | |
|---|---|
| Revenue | SEK 3.41m |
| Cost of Revenue | SEK 2.06m |
| Gross Profit | SEK 1.35m |
| Other Expenses | SEK 8.48m |
| Earnings | -SEK 7.14m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 21, 2024
| Earnings per share (EPS) | -0.067 |
| Gross Margin | 39.50% |
| Net Profit Margin | -209.58% |
| Debt/Equity Ratio | -661.0% |
How did ALTE perform over the long term?
See historical performance and comparison